It’s been a tough 13-plus months for Perrigo since John Hendrickson stepped in for departing CEO Joseph Papa. And now, the company is getting another change at the top.
Monday, the Dublin drugmaker announced that Hendrickson would retire and that it had set up a search committee to tap his replacement. Until it can, Hendrickson will stay on, and he’ll remain with the company for 60 days beyond that point to ease the transition.
“I am privileged to have led Perrigo, particularly as we’ve met the challenges we faced and stabilized the business in a time of transition,” he said in a statement.
Some analysts, though, may not agree with Hendrickson’s assessment of Perrigo’s business. Earlier Monday, RBC Capital Markets downgraded the stock to underperforom, with analyst Randall Stanicky calling erosion of Perrigo’s core consumer business “a new structural reality that has and will continue to largely offset new launch growth.”
The retirement adds “additional near-term uncertainty” to the story,” he wrote to clients Monday evening.
And just a few days before, Barclays’ Doug Tsao lowered his price target after reviewing delayed Q1 results, “recognizing turnaround and value unlock will take time.”
Hendrickson’s time at the helm started off on a shaky note for investors, with the new chief exec blasting Papa for an “unacceptable” recent track record of missing Perrigo’s own expectations–and slashing full-year earnings guidance to underscore the point that those expectations had been unrealistic from the get-go.
Not long after, shareholders sued the company for persuading them out of a Mylan sale they alleged would have left them in a better position.
Then, there was the activist pressure that ultimately forced a sale of the company’s royalty stream on Biogen multiple sclerosis med Tysabri and handed five boardroom seats to Starboard Value–including one for the proxy brawler’s CEO.
And then the layoffs came, first in Belgium at struggling recent buy Omega Pharma, and then across the company’s nonproduction workforce. In late February, Perrigo announced that it had approved a plan to chop 750 jobs.
With all of that in mind, whoever takes the reins from Hendrickson will have plenty on his or her plate. “Turnaround and value unlock will take time,” Barclays analyst Doug Tsao, who lowered his price target after reviewing the company’s Q1 results, wrote earlier this month.
By Carly Helfand
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
